You are here

Article Text

Article menu

Download PDFPDF

Therapeutics/Prevention
Randomised controlled trial
ABT-450/r-ombitasvir and dasabuvir with ribavirin eliminates viraemia in most patients with HCV infection with cirrhosis
Free
  1. Valérie Martel-Laferrière
  1. Microbiologie et Maladies Infectieuses, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada
  1. Correspondence to : Dr Valérie Martel-Laferrière, Microbiologie et Maladies Infectieuses, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, 1058 rue Saint-Denis, Montréal, Québec, Canada H2X 3J4; valerie.martel-laferriere{at}umontreal.ca

https://doi.org/10.1136/ebmed-2014-110055

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973–82.OpenUrlCrossRefPubMedWeb of Science

    Context

    The prevalence of hepatitis C virus (HCV) reached its peak in 1994 and is expected to decrease significantly over the next few years. However, HCV-related cirrhosis continues to increase. Razavi et al1 predicted that decompensated cirrhosis will reach its peak in 2019. This translates into increased healthcare costs secondary to complications of cirrhosis.

    Patients with cirrhosis due to HCV infection are less likely to achieve a sustained virological response (SVR), even in the era of direct-acting antivirals (DAA). Only 62% of genotype-3 cirrhotics treated with sofosbuvir and ribavirin for 24 weeks achieved SVR compared with 87% of non-cirrhotics.2 Treatment of advanced cirrhosis brings increased risks of …

    View Full Text